Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

A Study of the Safety and Effectiveness of Risperidone Versus Placebo for the Treatment of Conduct Disorder in Children With Mild, Moderate, or Borderline Mental Retardation

This study has been completed.
Information provided by:
Janssen Pharmaceutica N.V., Belgium Identifier:
First received: December 16, 2005
Last updated: January 20, 2011
Last verified: January 2011